Exact Mass: 447.31134360000004

C27H42NO2. Cl (447.29039020000005)

J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01G - Aminoglycoside antibacterials D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D005839 - Gentamicins C784 - Protein Synthesis Inhibitor > C2363 - Aminoglycoside Antibiotic D004791 - Enzyme Inhibitors > D011500 - Protein Synthesis Inhibitors C254 - Anti-Infective Agent > C258 - Antibiotic KEIO_ID S047; [MS3] KO009246 KEIO_ID S047; [MS2] KO009245 KEIO_ID S047

benzethonium chloride

D - Dermatologicals > D08 - Antiseptics and disinfectants > D08A - Antiseptics and disinfectants > D08AJ - Quaternary ammonium compounds C254 - Anti-Infective Agent > C28394 - Topical Anti-Infective Agent D000890 - Anti-Infective Agents Same as: D01140 Benzethonium chloride inhibits nicotinic acetylcholine receptors in human recombinant α7 and α4β2 neurons in Xenopus laevis oocytes.

N-Stearoyl tyrosine

(2S)-2-[(1-hydroxyoctadecylidene)amino]-3-(4-hydroxyphenyl)propanoic acid

N-stearoyl tyrosine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Stearic acid amide of Tyrosine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Stearoyl tyrosine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Stearoyl tyrosine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

(8Z,11Z,14Z,17Z)-Icosa-8,11,14,17-tetraenoylcarnitine

3-(icosa-8,11,14,17-tetraenoyloxy)-4-(trimethylazaniumyl)butanoate

(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoylcarnitine is an acylcarnitine. More specifically, it is an (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

Sisomicin sulfate

Esculeogenin A

5-(hydroxymethyl)-7,9,13-trimethyl-5-oxaspiro[pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane-6,2-piperidine]-3,16-diol

C28H49NOS (447.35346640000006)

N-[2,6-Di(propan-2-yl)phenyl]-2-tetradecylsulfanylacetamide

N-[2,6-bis(propan-2-yl)phenyl]-2-(tetradecylsulfanyl)acetamide

Lilopristone

17-[4-(dimethylamino)phenyl]-14-hydroxy-14-(3-hydroxyprop-1-en-1-yl)-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-1,6-dien-5-one

16-feruloyloxypalmitate

4-{3-[(15-carboxypentadecyl)oxy]-3-oxoprop-1-en-1-yl}-2-methoxybenzen-1-olic acid

C26H39O6 (447.2746494)

16-feruloyloxypalmitate is practically insoluble (in water) and a weakly acidic compound (based on its pKa). 16-feruloyloxypalmitate can be found in a number of food items such as mixed nuts, kiwi, soft-necked garlic, and sunflower, which makes 16-feruloyloxypalmitate a potential biomarker for the consumption of these food products.

Dehydrobicoloridine

(+)-Dehydrobicoloridine

(6Z,13E,21E)-(16R,20R)-20-hydroxy-16-methyl-10-phenyl-[14]cytochalasa-6,13,21-triene-1,23-dione

(1alpha,7beta,14alpha,16beta)-20-ethyl-1,8,16-trimethoxy-4-methylaconitan-14-yl acetate|14-acetoxy-8-O-methylsachaconitine

Esculeogenin B

N-(3alpha-Hydroxy-7-oxo-5beta-cholanoyl-(24))-glycin|nutriaglycocholic acid|Nutriaglykocholsaeure

C19H37N5O7

L-Arachidonoylcarnitine

Nakijiquinone P/Q

verticinone

Origin: Plant; SubCategory_DNP: Steroidal alkaloids, Veratrum alkaloids

Arachidonoyl-carnitine; AIF; CE0; CorrDec

Arachidonoyl-carnitine; AIF; CE10; CorrDec

Arachidonoyl-carnitine; AIF; CE30; CorrDec

Arachidonoyl-carnitine; AIF; CE0; MS2Dec

Arachidonoyl-carnitine; AIF; CE10; MS2Dec

Arachidonoyl-carnitine; AIF; CE30; MS2Dec

Arachidonoyl-carnitine; LC-tDDA; CE10

Arachidonoyl-carnitine; LC-tDDA; CE20

Arachidonoyl-carnitine; LC-tDDA; CE40

Arachidonoyl-carnitine; LC-tDDA; CE30

N-((4R)-4-((3R,5S,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)-N-methylglycine

"N-((4R)-4-((3R,5S,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)-N-methylglycine"

Ile Lys Ser Thr

(2S,3R)-2-[(2S)-2-[(2S)-6-amino-2-[(2S,3S)-2-amino-3-methylpentanamido]hexanamido]-3-hydroxypropanamido]-3-hydroxybutanoic acid

Ile Lys Thr Ser

(2S)-2-[(2S,3R)-2-[(2S)-6-amino-2-[(2S,3S)-2-amino-3-methylpentanamido]hexanamido]-3-hydroxybutanamido]-3-hydroxypropanoic acid

Ile Ser Lys Thr

(2S,3R)-2-[(2S)-6-amino-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-hydroxypropanamido]hexanamido]-3-hydroxybutanoic acid

Ile Ser Thr Lys

(2S)-6-amino-2-[(2S,3R)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-hydroxypropanamido]-3-hydroxybutanamido]hexanoic acid

Ile Thr Lys Ser

(2S)-2-[(2S)-6-amino-2-[(2S,3R)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-hydroxybutanamido]hexanamido]-3-hydroxypropanoic acid

Ile Thr Ser Lys

(2S)-6-amino-2-[(2S)-2-[(2S,3R)-2-[(2S,3S)-2-amino-3-methylpentanamido]-3-hydroxybutanamido]-3-hydroxypropanamido]hexanoic acid

Lys Ile Ser Thr

(2S,3R)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2,6-diaminohexanamido]-3-methylpentanamido]-3-hydroxypropanamido]-3-hydroxybutanoic acid

Lys Ile Thr Ser

(2S)-2-[(2S,3R)-2-[(2S,3S)-2-[(2S)-2,6-diaminohexanamido]-3-methylpentanamido]-3-hydroxybutanamido]-3-hydroxypropanoic acid

Lys Leu Ser Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-4-methylpentanamido]-3-hydroxypropanamido]-3-hydroxybutanoic acid

Lys Leu Thr Ser

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-4-methylpentanamido]-3-hydroxybutanamido]-3-hydroxypropanoic acid

Lys Ser Ile Thr

(2S,3R)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-hydroxypropanamido]-3-methylpentanamido]-3-hydroxybutanoic acid

Lys Ser Leu Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-hydroxypropanamido]-4-methylpentanamido]-3-hydroxybutanoic acid

Lys Ser Thr Ile

(2S,3S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-hydroxypropanamido]-3-hydroxybutanamido]-3-methylpentanoic acid

Lys Ser Thr Leu

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-hydroxypropanamido]-3-hydroxybutanamido]-4-methylpentanoic acid

Lys Thr Ile Ser

(2S)-2-[(2S,3S)-2-[(2S,3R)-2-[(2S)-2,6-diaminohexanamido]-3-hydroxybutanamido]-3-methylpentanamido]-3-hydroxypropanoic acid

Lys Thr Leu Ser

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2,6-diaminohexanamido]-3-hydroxybutanamido]-4-methylpentanamido]-3-hydroxypropanoic acid

Lys Thr Ser Ile

(2S,3S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2,6-diaminohexanamido]-3-hydroxybutanamido]-3-hydroxypropanamido]-3-methylpentanoic acid

Lys Thr Ser Leu

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2,6-diaminohexanamido]-3-hydroxybutanamido]-3-hydroxypropanamido]-4-methylpentanoic acid

Lys Thr Thr Val

(2S)-2-[(2S,3R)-2-[(2S,3R)-2-[(2S)-2,6-diaminohexanamido]-3-hydroxybutanamido]-3-hydroxybutanamido]-3-methylbutanoic acid

Lys Thr Val Thr

(2S,3R)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2,6-diaminohexanamido]-3-hydroxybutanamido]-3-methylbutanamido]-3-hydroxybutanoic acid

Lys Val Thr Thr

(2S,3R)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-methylbutanamido]-3-hydroxybutanamido]-3-hydroxybutanoic acid

Leu Lys Ser Thr

(2S,3R)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-4-methylpentanamido]hexanamido]-3-hydroxypropanamido]-3-hydroxybutanoic acid

Leu Lys Thr Ser

(2S)-2-[(2S,3R)-2-[(2S)-6-amino-2-[(2S)-2-amino-4-methylpentanamido]hexanamido]-3-hydroxybutanamido]-3-hydroxypropanoic acid

Leu Ser Lys Thr

(2S,3R)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-hydroxypropanamido]hexanamido]-3-hydroxybutanoic acid

Leu Ser Thr Lys

(2S)-6-amino-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-3-hydroxypropanamido]-3-hydroxybutanamido]hexanoic acid

Leu Thr Lys Ser

(2S)-2-[(2S)-6-amino-2-[(2S,3R)-2-[(2S)-2-amino-4-methylpentanamido]-3-hydroxybutanamido]hexanamido]-3-hydroxypropanoic acid

Leu Thr Ser Lys

(2S)-6-amino-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-4-methylpentanamido]-3-hydroxybutanamido]-3-hydroxypropanamido]hexanoic acid

Ser Ile Lys Thr

(2S,3R)-2-[(2S)-6-amino-2-[(2S,3S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-methylpentanamido]hexanamido]-3-hydroxybutanoic acid

Ser Ile Thr Lys

(2S)-6-amino-2-[(2S,3R)-2-[(2S,3S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-methylpentanamido]-3-hydroxybutanamido]hexanoic acid

Ser Lys Ile Thr

(2S,3R)-2-[(2S,3S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-hydroxypropanamido]hexanamido]-3-methylpentanamido]-3-hydroxybutanoic acid

Ser Lys Leu Thr

(2S,3R)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-hydroxypropanamido]hexanamido]-4-methylpentanamido]-3-hydroxybutanoic acid

Ser Lys Thr Ile

(2S,3S)-2-[(2S,3R)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-hydroxypropanamido]hexanamido]-3-hydroxybutanamido]-3-methylpentanoic acid

Ser Lys Thr Leu

(2S)-2-[(2S,3R)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-hydroxypropanamido]hexanamido]-3-hydroxybutanamido]-4-methylpentanoic acid

Ser Leu Lys Thr

(2S,3R)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-4-methylpentanamido]hexanamido]-3-hydroxybutanoic acid

Ser Leu Thr Lys

(2S)-6-amino-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-4-methylpentanamido]-3-hydroxybutanamido]hexanoic acid

Ser Thr Ile Lys

(2S)-6-amino-2-[(2S,3S)-2-[(2S,3R)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-hydroxybutanamido]-3-methylpentanamido]hexanoic acid

Ser Thr Lys Ile

(2S,3S)-2-[(2S)-6-amino-2-[(2S,3R)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-hydroxybutanamido]hexanamido]-3-methylpentanoic acid

Ser Thr Lys Leu

(2S)-2-[(2S)-6-amino-2-[(2S,3R)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-hydroxybutanamido]hexanamido]-4-methylpentanoic acid

Ser Thr Leu Lys

(2S)-6-amino-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-hydroxybutanamido]-4-methylpentanamido]hexanoic acid

Thr Ile Lys Ser

(2S)-2-[(2S)-6-amino-2-[(2S,3S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-methylpentanamido]hexanamido]-3-hydroxypropanoic acid

Thr Ile Ser Lys

(2S)-6-amino-2-[(2S)-2-[(2S,3S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-methylpentanamido]-3-hydroxypropanamido]hexanoic acid

Thr Lys Ile Ser

(2S)-2-[(2S,3S)-2-[(2S)-6-amino-2-[(2S,3R)-2-amino-3-hydroxybutanamido]hexanamido]-3-methylpentanamido]-3-hydroxypropanoic acid

Thr Lys Leu Ser

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S,3R)-2-amino-3-hydroxybutanamido]hexanamido]-4-methylpentanamido]-3-hydroxypropanoic acid

Thr Lys Ser Ile

(2S,3S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S,3R)-2-amino-3-hydroxybutanamido]hexanamido]-3-hydroxypropanamido]-3-methylpentanoic acid

Thr Lys Ser Leu

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S,3R)-2-amino-3-hydroxybutanamido]hexanamido]-3-hydroxypropanamido]-4-methylpentanoic acid

Thr Lys Thr Val

(2S)-2-[(2S,3R)-2-[(2S)-6-amino-2-[(2S,3R)-2-amino-3-hydroxybutanamido]hexanamido]-3-hydroxybutanamido]-3-methylbutanoic acid

Thr Lys Val Thr

(2S,3R)-2-[(2S)-2-[(2S)-6-amino-2-[(2S,3R)-2-amino-3-hydroxybutanamido]hexanamido]-3-methylbutanamido]-3-hydroxybutanoic acid

Thr Leu Lys Ser

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-4-methylpentanamido]hexanamido]-3-hydroxypropanoic acid

Thr Leu Ser Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-4-methylpentanamido]-3-hydroxypropanamido]hexanoic acid

Thr Ser Ile Lys

(2S)-6-amino-2-[(2S,3S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-hydroxypropanamido]-3-methylpentanamido]hexanoic acid

Thr Ser Lys Ile

(2S,3S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-hydroxypropanamido]hexanamido]-3-methylpentanoic acid

Thr Ser Lys Leu

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-hydroxypropanamido]hexanamido]-4-methylpentanoic acid

Thr Ser Leu Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-hydroxypropanamido]-4-methylpentanamido]hexanoic acid

Thr Thr Lys Val

(2S)-2-[(2S)-6-amino-2-[(2S,3R)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-hydroxybutanamido]hexanamido]-3-methylbutanoic acid

Thr Thr Val Lys

(2S)-6-amino-2-[(2S)-2-[(2S,3R)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-hydroxybutanamido]-3-methylbutanamido]hexanoic acid

Thr Val Lys Thr

(2S,3R)-2-[(2S)-6-amino-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-methylbutanamido]hexanamido]-3-hydroxybutanoic acid

Thr Val Thr Lys

(2S)-6-amino-2-[(2S,3R)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-methylbutanamido]-3-hydroxybutanamido]hexanoic acid

Val Lys Thr Thr

(2S,3R)-2-[(2S,3R)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-methylbutanamido]hexanamido]-3-hydroxybutanamido]-3-hydroxybutanoic acid

Val Thr Lys Thr

(2S,3R)-2-[(2S)-6-amino-2-[(2S,3R)-2-[(2S)-2-amino-3-methylbutanamido]-3-hydroxybutanamido]hexanamido]-3-hydroxybutanoic acid

Val Thr Thr Lys

(2S)-6-amino-2-[(2S,3R)-2-[(2S,3R)-2-[(2S)-2-amino-3-methylbutanamido]-3-hydroxybutanamido]-3-hydroxybutanamido]hexanoic acid

2-docosanamidoethanesulfonic acid

N-docosanoyl taurine

N-stearoyl tyrosine

N-octadecanoyl-tyrosine

C28H33D8NO3 (447.35884502400006)

N-Arachidonoyl Dopamine-d8

CAR 20:4

3-[(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoyloxy]-4-(trimethylazaniumyl)butanoate

NAT 22:0

N-docosanoyl-taurine

NA 27:5;O3

N-hexadecanoyl-alpha,O-dimethyl-L-tyrosine

C28H33D8NO3 (447.35884502400006)

N-arachidonoyl-dopamine-d8

N-[2-(3,4-dihydroxyphenyl)ethyl]-5Z,8Z,11Z,14Z-eicosatetraenamide-5,6,8,9,11,12,14,15-d8

ST 24:2;O4;G

N-(3beta,7beta,dihydroxycholest-5-en-24-oyl) glycine

Viaminate

C26H33N5O2 (447.26341180000003)

Methyltrioctylammonium bromide

C25H54BrN (447.3439384)

2-[4-[[1-(3-oxo-3-phenylpropyl)benzimidazol-2-yl]methyl]piperazin-1-yl]-N-propan-2-ylacetamide

hexadecyl-(2-hydroxycyclohexyl)-dimethylazanium,bromide

C24H50BrNO (447.30755500000004)

Stevaladil

C27H42ClNO2 (447.29039020000005)

benzethonium chloride

D - Dermatologicals > D08 - Antiseptics and disinfectants > D08A - Antiseptics and disinfectants > D08AJ - Quaternary ammonium compounds C254 - Anti-Infective Agent > C28394 - Topical Anti-Infective Agent D000890 - Anti-Infective Agents Benzethonium chloride inhibits nicotinic acetylcholine receptors in human recombinant α7 and α4β2 neurons in Xenopus laevis oocytes.

LOVASTATIN HYDROXY ACID, SODIUM SALT

C24H34D3NaO6 (447.26760173400004)

lilopristone

N-Stearoyltyrosine

7-Oxoglycochenodeoxycholic acid

D005765 - Gastrointestinal Agents > D001647 - Bile Acids and Salts D005765 - Gastrointestinal Agents > D002793 - Cholic Acids

4,6-Diamino-3-{[3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl]oxy}-2-hydroxycyclohexyl 3-deoxy-4-c-methyl-3-(methylamino)pentopyranoside

D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D005839 - Gentamicins D004791 - Enzyme Inhibitors > D011500 - Protein Synthesis Inhibitors

Arachidonoylcarnitine

16-feruloyloxypalmitate

C26H39O6- (447.2746494)

(2S,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol

11-[4-(dimethylamino)phenyl]-17-hydroxy-17-[(E)-3-hydroxyprop-1-enyl]-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one

(8Z,11Z,14Z,17Z)-Icosa-8,11,14,17-tetraenoylcarnitine

Esculeogenin A

A sapogenin that is spirosolane substituted by hydroxy groups at positions 3, 23 and 27 (the 3beta,5alpha,22alpha,23S,25S stereoisomer).

(2S,3R,4S,5S)-2-[(1R,2S,3S,4R,6S)-4,6-diamino-3-[[3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol

(4E,6Z)-N-(5-ethyl-5-methyl-2-oxofuran-3-yl)-3-hydroxy-8-(3-nonyloxiran-2-yl)octa-4,6-dienamide

C28H35N2O3+ (447.26475400000004)

4-[2-[2,4-Bis(4-ethoxyphenyl)-6-methyl-1-pyridin-1-iumyl]ethyl]morpholine

N-[(5R,6S,9R)-8-(cyclopropylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide

N-[(5S,6R,9R)-8-(cyclopropylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide

N-[(5R,6R,9R)-8-(cyclopropylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide

N-[(5S,6R,9S)-8-(cyclopropylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide

N-[(5S,6R,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide

N-[(5S,6S,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide

N-[(5R,6S,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide

N-[(4S,7R,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide

N-[(4R,7S,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide

N-((4R)-4-((3R,5S,9S,10S,13R,14S,17R)-3-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)-N-methylglycine

N-[(5R,6R,9S)-8-(cyclopropylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide

N-[(5S,6S,9S)-8-(cyclopropylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide

N-[(5S,6S,9R)-8-(cyclopropylmethyl)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide

N-[(5R,6R,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide

N-[(5R,6R,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide

N-[(5S,6S,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide

N-[(5S,6R,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide

N-[(4R,7R,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide

N-[(4S,7S,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide

N-[(4R,7R,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide

N-[(4R,7S,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide

N-[(4S,7S,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide

N-[(4S,7R,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide

3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxy-4-(trimethylazaniumyl)butanoate

HexCer 9:1;2O/7:0

Ldgcc 13:0

C23H45NO7 (447.319586)

HexCer 8:1;2O/8:0

HexCer 10:1;2O/6:0

HexCer 13:1;2O/3:0

HexCer 14:1;2O/2:0

HexCer 12:1;2O/4:0

HexCer 11:1;2O/5:0

C22H41NO6S (447.2654446000001)

(E)-3-hydroxy-2-[[(Z)-2-hydroxydodec-5-enoyl]amino]dec-4-ene-1-sulfonic acid

3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]decane-1-sulfonic acid

(E)-3-hydroxy-2-(undecanoylamino)dodec-4-ene-1-sulfonic acid

(E)-2-(dodecanoylamino)-3-hydroxyundec-4-ene-1-sulfonic acid

(E)-2-(decanoylamino)-3-hydroxytridec-4-ene-1-sulfonic acid

(E)-3-hydroxy-2-(tridecanoylamino)dec-4-ene-1-sulfonic acid

C30H41NO2 (447.31371260000003)

cis-5-(6-Formylhexyl)-trans-4-(cis-1-octenyl)-2,ref.-3-diphenylisoxazolidine

(10S)-10,20-dihydroxy-6,10,23-trimethyl-4-azahexacyclo[12.11.0.02,11.04,9.015,24.018,23]pentacosan-17-one;hydrate

C21H40N2O6P+ (447.26238500000005)

2-[[(4E,8E,12E)-2-acetamido-3-hydroxytetradeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

O-arachidonoylcarnitine

An O-acylcarnitine having arachidonoyl as the acyl substituent.

sisomycin

N-docosanoyltaurine

C23H46NO5P (447.31134360000004)

A fatty acid-taurine conjugate derived from docosanoic acid.

SPHP(23:2)

SPHP(d23:2)

NA-2AAA 20:4(5Z,8Z,11Z,14Z)

NA-Asp 22:4(7Z,10Z,13Z,16Z)

NA-DOPA 17:1(9Z)

C26H45N3O3 (447.34607400000004)

NA-His 20:1(11Z)

NA-PABA 22:6(4Z,7Z,10Z,13Z,16Z,19Z)

NA-Taurine 22:0

NA-Tyr 18:0

MGCC 13:0

C23H45NO7 (447.319586)

ST 23:3;O4;Gly

ST 24:2;O3;Gly

ST 25:1;O2;Gly

(9s,12ar,15r,15as,16r,18as)-16-benzyl-18-hydroxy-9,14,15-trimethyl-5h,6h,7h,8h,9h,10h,12ah,15h,15ah,16h-oxacyclotetradeca[3,2-d]isoindol-2-one

3-{[(1r,2s,4as,8as)-1,2,4a-trimethyl-5-methylidene-hexahydro-2h-naphthalen-1-yl]methyl}-2-hydroxy-5-[(2-phenylethyl)amino]cyclohexa-2,5-diene-1,4-dione

(2r)-3-[(2r,4e)-4-{[(1s,2r,4ar,6r,8s,8ar)-2-[(2e)-but-2-en-2-yl]-6,8-dimethyl-decahydronaphthalen-1-yl](hydroxy)methylidene}-5-hydroxy-3-oxo-2h-pyrrol-2-yl]-2-hydroxy-2-methylpropanoic acid

C30H41NO2 (447.31371260000003)

(1s,12s,15r,16s,17s,20s)-1,16,20-trimethyl-16-(4-methylpent-3-en-1-yl)-3-azapentacyclo[10.8.0.0²,¹⁰.0⁴,⁹.0¹⁵,²⁰]icosa-2(10),4,6,8-tetraen-17-yl acetate

(1r,2r,3ar,3br,5as,7s,9ar,9br,11as)-2,7-dihydroxy-1-[(1s)-1-[(2s,3r,5s)-3-hydroxy-5-methylpiperidin-2-yl]ethyl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-6-one

(3s)-12-[(1-hydroxy-4,6-dimethoxy-3h-isoindol-5-yl)oxy]-2,6,10-trimethyldodeca-6,10-diene-2,3-diol

(1s,2r,5s,7s,10s,11s,14s,15r,16s,17s,20s,22r,24s)-20-(hydroxymethyl)-10,14,16-trimethyl-23-oxa-18-azahexacyclo[12.11.0.0²,¹¹.0⁵,¹⁰.0¹⁵,²⁴.0¹⁷,²²]pentacosane-7,22-diol

2-[(1-hydroxyhexadecylidene)amino]-3-(4-methoxyphenyl)-2-methylpropanoic acid

alkaloid f3